Quintiles announced an agreement to help accelerate the development of new and more effective medicines. Southern California Permanente Medical Group will join Quintiles’ three other prime sites globally, selected for their long-term commitment to clinical research.
Clinical research professionals from both Quintiles and SCPMG will work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site.
Donald S. Fong, MD, MPH, Director of Clinical Trials, SCPMG Department of Research & Evaluation, Kaiser Permanente Southern California says, “The Southern California Permanente Clinical Trials program works on the premise that all clinical trials research should focus on advancing the practice of medical care to improve health outcomes through rigorously designed and executed trials.
“Southern California Permanente Clinical Trial investigators are practicing physicians who use their clinical acumen and methodological training to bridge the gap between basic research and clinical practice. Typically, clinical trials research in Kaiser Permanente is aimed at evaluating the impact of interventions at the bedside. This perspective ensures that trials address meaningful questions.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.